Consolidated Statements of Operations and Comprehensive Loss - Schedule of Research and Development Expenses (Details) - EUR (€) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Schedule of Research and Development Expenses [Line Items] | |||
| Total research and development expenses | € 25,720,788 | € 35,363,897 | € 41,024,131 |
| Third-party expenses [Member] | |||
| Schedule of Research and Development Expenses [Line Items] | |||
| Total research and development expenses | 15,878,926 | 23,113,874 | 31,802,983 |
| Personnel expenses [Member] | |||
| Schedule of Research and Development Expenses [Line Items] | |||
| Total research and development expenses | 8,215,944 | 8,390,010 | 6,776,853 |
| Equity-settled share-based payment expense [Member] | |||
| Schedule of Research and Development Expenses [Line Items] | |||
| Total research and development expenses | 1,723,421 | 1,873,958 | 1,500,670 |
| Other expenses [Member] | |||
| Schedule of Research and Development Expenses [Line Items] | |||
| Total research and development expenses | € 1,625,918 | € 3,860,013 | € 2,444,295 |